Meeting
2017 ASCO Annual Meeting
Evaluation of tumor and circulating cell free (cf) DNA mutations in women with hormone refractory metastatic breast cancer (MBC) enrolled in a phase I study of Z-endoxifen (MC093C).
Authors
Matthew P. Goetz
Mayo Clinic, Rochester, MN
Matthew P. Goetz , Vera J. Suman , Joel M. Reid , Donald W. Northfelt , Sarah A Burhow , Stephanie L. Safgren , Renee M. McGovern , Travis J. Dockter , Tufia C. Haddad , Charles Erlichman , Alex A. Adjei , Daniel W. Visscher , Benjamin Kipp , John Hawse , James H. Doroshow , Jerry M. Collins , Matthew M. Ames , James N. Ingle , Minetta C. Liu , Howard Streicher
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT01327781
Citation
J Clin Oncol 35, 2017 (suppl; abstr 1043)
DOI
10.1200/JCO.2017.35.15_suppl.1043
Abstract #
1043
Poster Bd #
35
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer (mBC).
First Author: Lajos Pusztai
Poster
2023 ASCO Annual Meeting
ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer.
First Author: Arielle J Medford
Poster
2020 ASCO Virtual Scientific Program
Cell-free DNA comparative analysis of hormone receptor-positive, first-line metastatic breast cancer genomic landscape in the United States and China.
First Author: Huiping Li
Poster
2020 ASCO Virtual Scientific Program
Biomarker analysis from a phase I study using gedatolisib+palbociclib+hormone therapy in ER+/HER2- metastatic breast cancer (mBC).
First Author: Robert Wesolowski